Pierre Dönnes

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Part of Pfizer Inc., Pharmacia AB /Hillerod Unit/ is a pharmaceutical company based in Hillerod, Sweden. Pharmacia AB /Hillerod Unit was acquired by Pharmacia AB /Hillerod UnitManagement/ on January 10, 2001.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.

Institutet för Personal- och Företagsutveckling AB engages in the provision of human resources related services. The firm bridges the gap between theory and practice within organizational development, leadership growth, and human resource management. The company was founded in 1986 and is headquartered in Uppsala, Sweden.

NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden.

AddBIO AB provides bone implant technology solutions. It offers Zolidd, a bioactive nanolayer with a bone strengthening drug. The firm's Zolidd is used in the areas of dental and trauma implants. It also offers Zolidiser, a machine to add bone-strengthening drugs to implants. The company was founded by Per Aspenberg and Trine Vikinge in 2008 and is headquartered in Linköping, Sweden.

Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden.

Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013.

Cormorant Pharmaceuticals AB provides biopharmaceutical products.The company was founded by Maarten de Chateau and Urban Paulsson in 2010 and is headquartered in Solna, Sweden.

Disruptive Materials AB manufactures mesoporous magnesium carbonate. It focuses on commercializing the material Upsalite that can be used in applications such as desiccant for humidity control, pharmaceutics, adsorbent for waste handling, thermal and acoustic insulation, cosmetics, adsorbent in ink jet paper,and bio material applications. The company was founded by Johan A. V. Gómez de la Torre, Maria Strømme, Lars-Erik Mattias Karls, and Sara Kristina Frykstrand Ångström in December 2011 and is headquartered in Uppsala, Sweden.

Atrogi AB engages in research and development & sells type 2 diabetes (T2D) with minimal side effects. The company was founded by Tore Bengtsson and Andreas Bhagwani in 2013 and is headquartered in Solna, Sweden.

Immuneed AB develops drugs. The firm offers as a contract research organization and provides specialized services for immunotoxicology and immunophenotyping. Its services include cytokine release assay, complement activation, cellular drug biodistribution, cell activation patterns, immune recall responses, viability analyses, blood status and mode-of-action studies. The company was founded by Sara Mangsbo, Erika Fletcher and Thomas Totterman in 2014 and is headquartered in Uppsala, Sweden.

Sixera Pharma AB conducts activities within research, development, and commercialization of pharmaceuticals. It develops treatment for Netherton syndrome. The company was founded by Jean Nordstrom on August 21, 2012 and is headquartered in Göteborg, Sweden.

Haracon AB provides corporate consulting services.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.

Nylof Holding AB provides security brokerage services. The private company is based in Stockholm, Sweden.

Uppsala Universitets Projekt AB is a company whose name translates to "Uppsala University Project Ltd." It is likely a subsidiary or affiliated company of Uppsala University, a research university located in Uppsala, Sweden. However, without further information, it is unclear what specific projects or services Uppsala Universitets Projekt provides.

Uppsala Universitet Research Intellectual Property AB provides research and development services in the fields of social sciences and humanities.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022.

Trailhead Biosystems, Inc. develops cell therapies. Its program includes cancer immunotherapy, bone induction, neural fate space project, kidney and blood program. The company was founded by Jan Jensen in 2013 and is headquartered in Cleveland, OH.

Buzzard Pharmaceuticals AB develops oncology drugs. The company is based in Stockholm, Sweden. The Swedish company was founded by Urban Paulsson. The CEO is Maarten de Château.

Disruptive Pharma AB is a pharmaceutical company based in Uppsala, Sweden, with a passion for innovation in drug products. The Swedish company has perfected the groundbreaking mesoporous magnesium carbonate (mmc) drug delivery technology, which makes it easier to develop amorphous drug candidates. By combining the mmc formulation technology with drug compounds, they can enhance existing products or assist in formulating new therapies. Disruptive Pharma seeks commercial partnership or licensing to industry partners within the drug improvement business area. The company was founded in 2018 by Maria Strömme, and the CEO is Peter Åsberg.

VivoLogica AB specializes in providing a comprehensive tool for data collection, analysis, compliance, and reporting for research purposes. The company is based in Stockholm, Sweden. The Swedish company offers a platform that enables researchers to have full control over their research data and provides scientific output in one tool. The company was founded by Sara Mangsbo, and the CEO is Martina Banyay.